Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension

This study has been completed.
Sponsor:
Information provided by:
Takeda
ClinicalTrials.gov Identifier:
NCT01289132
First received: February 1, 2011
Last updated: NA
Last verified: February 2011
History: No changes posted

February 1, 2011
February 1, 2011
July 2007
July 2008   (final data collection date for primary outcome measure)
Change from Baseline in Sitting Trough Diastolic Blood Pressure (Week 12). [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
The change between sitting trough clinic diastolic blood pressure measured at week 12 or final visit from diastolic blood pressure measured at baseline. Trough is a time point immediately before the next administration where drug blood concentration is lowest. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
Same as current
No Changes Posted
  • Change from Baseline in Sitting Trough Diastolic Blood Pressure (Week 2). [ Time Frame: Baseline and Week 2. ] [ Designated as safety issue: No ]
    The change between sitting trough clinic diastolic blood pressure measured at week 2 from diastolic blood pressure measured at baseline. Trough is a time point immediately before the next administration where drug blood concentration is lowest. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
  • Change from Baseline in Sitting Trough Diastolic Blood Pressure (Week 4). [ Time Frame: Baseline and Week 4. ] [ Designated as safety issue: No ]
    The change between sitting trough clinic diastolic blood pressure measured at week 4 from diastolic blood pressure measured at baseline. Trough is a time point immediately before the next administration where drug blood concentration is lowest. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
  • Change from Baseline in Sitting Trough Diastolic Blood Pressure (Week 6). [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The change between sitting trough clinic diastolic blood pressure measured at week 6 from diastolic blood pressure measured at baseline. Trough is a time point immediately before the next administration where drug blood concentration is lowest. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
  • Change from Baseline in Sitting Trough Diastolic Blood Pressure (Week 8). [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change between sitting trough clinic diastolic blood pressure measured at week 8 from diastolic blood pressure measured at baseline. Trough is a time point immediately before the next administration where drug blood concentration is lowest. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
  • Change from Baseline in Sitting Trough Diastolic Blood Pressure (Week 10). [ Time Frame: Baseline and Week 10. ] [ Designated as safety issue: No ]
    The change between sitting trough clinic diastolic blood pressure measured at week 10 from diastolic blood pressure measured at baseline. Trough is a time point immediately before the next administration where drug blood concentration is lowest. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
  • Change from Baseline in Sitting Trough Systolic Blood Pressure (Week 2). [ Time Frame: Baseline and Week 2. ] [ Designated as safety issue: No ]
    The change between sitting trough clinic systolic blood pressure measured at week 2 from systolic blood pressure measured at baseline. Trough is a time point immediately before the next administration where drug blood concentration is lowest. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
  • Change from Baseline in Sitting Trough Systolic Blood Pressure (Week 4). [ Time Frame: Baseline and Week 4. ] [ Designated as safety issue: No ]
    The change between sitting trough clinic systolic blood pressure measured at week 4 from systolic blood pressure measured at baseline. Trough is a time point immediately before the next administration where drug blood concentration is lowest. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
  • Change from Baseline in Sitting Trough Systolic Blood Pressure (Week 6). [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The change between sitting trough clinic systolic blood pressure measured at week 6 from systolic blood pressure measured at baseline. Trough is a time point immediately before the next administration where drug blood concentration is lowest. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
  • Change from Baseline in Sitting Trough Systolic Blood Pressure (Week 8). [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change between sitting trough clinic systolic blood pressure measured at week 8 from systolic blood pressure measured at baseline. Trough is a time point immediately before the next administration where drug blood concentration is lowest. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
  • Change from Baseline in Sitting Trough Systolic Blood Pressure (Week 10). [ Time Frame: Baseline and Week 10. ] [ Designated as safety issue: No ]
    The change between sitting trough clinic systolic blood pressure measured at week 10 from systolic blood pressure measured at baseline. Trough is a time point immediately before the next administration where drug blood concentration is lowest. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
  • Change from Baseline in Sitting Trough Systolic Blood Pressure (Week 12). [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
    The change between sitting trough clinic systolic blood pressure measured at week 12 or final visit from systolic blood pressure measured at baseline. Trough is a time point immediately before the next administration where drug blood concentration is lowest. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit.
  • Number of Participants with a ≥20 mmHg Decrease in Sitting Trough Systolic Blood Pressure and a ≥10 mmHg Decrease in Sitting Trough Diastolic Blood Pressure. [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
    Number of participants designated as responders who have a ≥20 mmHg Decrease in sitting trough systolic blood pressure and a ≥10 mmHg Decrease in sitting trough diastolic blood pressure at week 12 or final visit from baseline.
  • Number of Participants with a Sitting Trough Systolic Blood Pressure of <130 mmHg and a Sitting Trough Diastolic Blood Pressure of <85 mmHg. [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
    Number of participants designated as responders with a sitting trough systolic blood pressure of <130 mmHg and a sitting trough diastolic blood pressure of <85 mmHg at week 12 or final visit from baseline.
  • Incidence of Adverse Events. [ Time Frame: On occurrence (up to Week 12). ] [ Designated as safety issue: Yes ]
    Treatment-emergent adverse events (TEAE) are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.
  • Change from Baseline in Supine Systolic Blood Pressure. [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: Yes ]
    The change between supine systolic blood pressure measured at week 12 or final visit from baseline. Supine systolic blood pressure is measured in participants laying on their back in a face-up position once after resting for 2 minutes.
  • Change from Baseline in Supine Diastolic Blood Pressure. [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: Yes ]
    The change between supine diastolic blood pressure measured at week 12 or final visit from baseline. Supine diastolic blood pressure is measured in participants laying on their back in a face-up position once after resting for 2 minutes.
  • Change from Baseline in Standing Systolic Blood Pressure. [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: Yes ]
    The change between standing systolic blood pressure measured at week 12 or final visit from baseline. Standing systolic blood pressure is measured once after participants keep a standing position for 1 minute.
  • Change from Baseline in Standing Diastolic Blood Pressure. [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: Yes ]
    The change between standing diastolic blood pressure measured at week 12 or final visit from baseline. Standing diastolic blood pressure is measured once after participants keep a standing position for 1 minute.
  • Change from Baseline in Sitting Pulse Rate. [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: Yes ]
    The change between sitting pulse rate measured at week 12 or final visit from baseline. Sitting pulse rate is measured at least 3 times in 1- to 2-minute intervals after sitting ≥5 minutes, repeated until 2 consecutive stable measurements are obtained.
  • Change from Baseline in Weight. [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: Yes ]
    The change between weight recorded at week 12 or final visit from baseline.
  • Change from Baseline in Resting 12-lead Electrocardiogram. [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: Yes ]
    The change between electrocardiogram recorded at week 12 or final visit from baseline. Electrocardiogram interpreted using one of the following categories: within normal limits, abnormal but not clinically significant, or abnormal and clinically significant.
  • Number of Participants with a Markedly Abnormal Blood Urea Nitrogen Clinical Laboratory Value. [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: Yes ]
    The number of participants with a markedly abnormal blood urea value nitrogen collected at week 12 or final visit from baseline.
  • Number of Participants with a Markedly Abnormal Uric Acid Clinical Laboratory Value. [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: Yes ]
    The number of participants with a markedly abnormal uric acid value collected at week 12 or final visit from baseline.
  • Number of Participants with a Markedly Abnormal Creatinine Clinical Laboratory Value. [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: Yes ]
    The number of participants with a markedly abnormal creatinine value collected at week 12 or final visit from baseline.
  • Number of Participants with a Markedly Abnormal Creatine Kinase Clinical Laboratory Value. [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: Yes ]
    The number of participants with a markedly abnormal creatine kinase value collected at week 12 or final visit from baseline.
Same as current
Not Provided
Not Provided
 
Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-536 in Subjects With Mild to Moderate Uncomplicated Essential Hypertension

The purpose of this study was to evaluate the dose-response relationships of azilsartan, once daily (QD) in participants with mild to moderate uncomplicated essential hypertension.

Hypertension is known to cause multiple organ damage by being combined with not only blood pressure but also other hemodynamics, endocrinological/metabolic abnormalities and genetic factors. This becomes a medically and medical-economically significant problem in Japan The significance of early treatment of hypertension and of long-term control of blood pressure has been increasing year by year.

Takeda Pharmaceutical Company Limited invented TAK-536 (azilsartan), an angiotensin II receptor blocker for decreasing blood pressure. This study investigating the efficacy and safety of azilsartan using candesartan cilexetil, a widely used antihypertensive drug, as a reference control.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Essential Hypertension
  • Drug: Placebo
    Placebo-matching tablets, orally, once daily for up to 12 weeks.
  • Drug: Azilsartan
    Azilsartan 5 mg, tablets, orally, once daily for up to 12 weeks.
    Other Name: TAK-536
  • Drug: Azilsartan
    Azilsartan 10 mg, tablets, orally, once daily for up to 12 weeks.
    Other Name: TAK-536
  • Drug: Azilsartan
    Azilsartan 20 mg, tablets, orally, once daily for up to 12 weeks.
    Other Name: TAK-536
  • Drug: Azilsartan
    Azilsartan 40 mg, tablets, orally, once daily for up to 12 weeks.
    Other Name: TAK-536
  • Drug: Azilsartan
    Azilsartan 80 mg, tablets, orally, once daily for up to 12 weeks.
    Other Name: TAK-536
  • Drug: Candesartan cilexetil
    Candesartan cilexetil 8 mg, tablets, orally, once daily for 4 weeks; titrated to 12 mg, tablets, orally, once daily for up to 8 weeks.
    Other Names:
    • Blopress®
    • TCV-116
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Experimental: Azilsartan 5 mg QD
    Intervention: Drug: Azilsartan
  • Experimental: Azilsartan 10 mg QD
    Intervention: Drug: Azilsartan
  • Experimental: Azilsartan 20 mg QD
    Intervention: Drug: Azilsartan
  • Experimental: Azilsartan 40 mg QD
    Intervention: Drug: Azilsartan
  • Experimental: Azilsartan 80 mg QD
    Intervention: Drug: Azilsartan
  • Active Comparator: Candesartan Cilexetil 8 mg titrated to12 mg QD
    Intervention: Drug: Candesartan cilexetil
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
926
July 2008
July 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Has mild to moderate uncomplicated essential hypertension.
  • Has a sitting diastolic blood pressure between 95 and <110 mmHg and sitting systolic blood pressure between 150 and <180 mmHg at placebo run-in period (Week -2) or randomization visit.

Exclusion Criteria:

  • Has a cardiovascular disease or symptoms
  • Has been treated with more than 3 different antihypertensives within 27 days prior to placebo run-in period.
  • Has a significant hepatic disorder, hyperkalemia, malignant tumor or significant renal impairment.
Both
20 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01289132
TAK-536/CCT-001, U1111-1118-3346
No
Sr. Manager, Clinical Planning, Takeda Pharmaceutical Company Limited (Japan)
Takeda
Not Provided
Study Director: Professor Geriatric Medicine and Nephrology Osaka University Graduate School of Medicine
Takeda
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP